Emergent BioSolutions Inc. – NYSE:EBS
Founder-led company
Emergent BioSolutions stock price today
$9.121
+0.85
+10.29%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 10 hours
Emergent BioSolutions stock price monthly change
-22.35%
month
Emergent BioSolutions stock price quarterly change
-22.35%
quarter
Emergent BioSolutions stock price yearly change
+244.58%
year
Emergent BioSolutions key metrics
Market Cap | 434.55M |
Enterprise value | 1.42B |
P/E | -2.87 |
EV/Sales | 1.26 |
EV/EBITDA | -34.60 |
Price/Sales | 0.58 |
Price/Book | 0.47 |
PEG ratio | 0.01 |
EPS | -11.06 |
Revenue | 1.18B |
EBITDA | 89.3M |
Income | -567.7M |
Revenue Q/Q | 81.95% |
Revenue Y/Y | 21.14% |
Profit margin | -19.97% |
Oper. margin | -14.81% |
Gross margin | 38.11% |
EBIT margin | -14.81% |
EBITDA margin | 7.53% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEmergent BioSolutions stock price history
Emergent BioSolutions stock forecast
Emergent BioSolutions financial statements
| Jun 2023 | 337.9M | -261.3M | -77.33% |
|---|---|---|---|
| Sep 2023 | 270.5M | -265.9M | -98.3% |
| Dec 2023 | 276.6M | -49.5M | -17.9% |
| Mar 2024 | 300.4M | 9M | 3% |
| 2027 | 904.5M | -51.71M | -5.72% |
|---|
Analysts Price target
Financials & Ratios estimates
| 2022-08-01 | 0.38 | -0.86 |
|---|---|---|
| 2022-11-08 | -0.06 | -1.27 |
| Jun 2023 | 2178800000 | 1.22B | 56.11% |
|---|---|---|---|
| Sep 2023 | 1893100000 | 1.19B | 63.17% |
| Dec 2023 | 1834900000 | 1.18B | 64.61% |
| Mar 2024 | 1803600000 | 1.13B | 63.19% |
| Jun 2023 | -114.4M | 257.7M | -486.9M |
|---|---|---|---|
| Sep 2023 | 60M | -18.9M | -43M |
| Dec 2023 | 32.1M | -11.4M | 4.7M |
| Mar 2024 | -62.6M | -10.8M | 40.7M |
Emergent BioSolutions alternative data
| Sep 2023 | 2,500 |
|---|---|
| Oct 2023 | 2,500 |
| Nov 2023 | 2,500 |
| Dec 2023 | 2,500 |
| Jan 2024 | 2,500 |
| Feb 2024 | 2,500 |
| Mar 2024 | 1,600 |
| Apr 2024 | 1,600 |
| May 2024 | 1,600 |
| Jun 2024 | 1,600 |
| Jul 2024 | 1,600 |
Emergent BioSolutions other data
65.17%
-15.37%
of EBS is owned by hedge funds
170
-48
32.58M
-8.24M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2024 | 0 | 2919 |
| Jun 2024 | 0 | 10000 |
| Nov 2024 | 0 | 39287 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | DEGOLYER DONALD W director | Common Stock | 25,000 | $10.91 | $272,750 | ||
Sale | WHITE MARVIN L director | Common Stock | 14,287 | $11.97 | $171,015 | ||
Sale | ZOON KATHRYN C director | Common Stock | 10,000 | $6.11 | $61,100 | ||
Sale | ZOON KATHRYN C director | Common Stock | 1,830 | $4.61 | $8,436 | ||
Sale | ZOON KATHRYN C director | Common Stock | 1,089 | $5.78 | $6,294 | ||
Sale | RICHARD RONALD director | Common Stock | 1,912 | $11.94 | $22,829 | ||
Sale | ZOON KATHRYN C director | Common Stock | 1,173 | $31.52 | $36,973 | ||
Sale | ZOON KATHRYN C director | Common Stock | 1,996 | $35.53 | $70,918 | ||
Purchase | LINDAHL RICHARD S officer: EVP, Chi.. | Common Stock | 3,000 | $37.46 | $112,380 | ||
Purchase | LINDAHL RICHARD S officer: EVP, Chi.. | Common Stock | 3,000 | $37.46 | $112,380 |
| Quarter | Transcript |
|---|---|
| Q1 2024 1 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 6 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
Emergent BioSolutions: Strategic Turnaround Proving Tricky, But I'm Still Hopeful
Emergent BioSolutions: Stock Is A Likely Winner In 2025
Emergent BioSolutions: Q3 Numbers Leave Work To Be Done
Emergent BioSolutions Is Clearly Risky, But The Reward Could Be Substantial
Emergent BioSolutions: A Turnaround In Sight With OTC Narcan Amidst Ongoing Opioid Crisis
Emergent BioSolutions: Positive NARCAN FDA Panel, Divesting Travel Health, Raising Rating To Buy
Opiant Pharmaceuticals: Nano-Cap Buyout With Interesting CVR Thrown In
Chimerix: A Confusing Business Strategy Makes It Unconvincing
Moderna 2.0: 3 Stocks To Play The Potential Monkeypox Pandemic
-
What's the price of Emergent BioSolutions stock today?
One share of Emergent BioSolutions stock can currently be purchased for approximately $9.12.
-
When is Emergent BioSolutions's next earnings date?
Unfortunately, Emergent BioSolutions's (EBS) next earnings date is currently unknown.
-
Does Emergent BioSolutions pay dividends?
No, Emergent BioSolutions does not pay dividends.
-
How much money does Emergent BioSolutions make?
Emergent BioSolutions has a market capitalization of 434.55M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 6.39% to 1.05B US dollars. Emergent BioSolutions made a loss 760.5M US dollars in net income (profit) last year or -$1.27 on an earnings per share basis.
-
What is Emergent BioSolutions's stock symbol?
Emergent BioSolutions Inc. is traded on the NYSE under the ticker symbol "EBS".
-
What is Emergent BioSolutions's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Emergent BioSolutions?
Shares of Emergent BioSolutions can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Emergent BioSolutions's key executives?
Emergent BioSolutions's management team includes the following people:
- Mr. Robert G. Kramer Chief Executive Officer, Pres & Executive Director(age: 68, pay: $2,130,000)
- Mr. Fuad El-Hibri Founder & Executive Chairman(age: 67, pay: $1,200,000)
- Mr. Richard S. Lindahl Executive Vice President, Chief Financial Officer & Treasurer(age: 61, pay: $1,020,000)
- Mr. Adam R. Havey Executive Vice President & Chief Operating Officer(age: 54, pay: $1,000,000)
- Mr. Atul Saran Executive Vice President of Corporation Devel. & Ext. Affairs and Gen. Counsel(age: 52, pay: $983,570)
-
Is Emergent BioSolutions founder-led company?
Yes, Emergent BioSolutions is a company led by its founder Mr. Fuad El-Hibri.
-
How many employees does Emergent BioSolutions have?
As Jul 2024, Emergent BioSolutions employs 1,600 workers.
-
When Emergent BioSolutions went public?
Emergent BioSolutions Inc. is publicly traded company for more then 18 years since IPO on 15 Nov 2006.
-
What is Emergent BioSolutions's official website?
The official website for Emergent BioSolutions is emergentbiosolutions.com.
-
Where are Emergent BioSolutions's headquarters?
Emergent BioSolutions is headquartered at 400 Professional Drive, Gaithersburg, MD.
-
How can i contact Emergent BioSolutions?
Emergent BioSolutions's mailing address is 400 Professional Drive, Gaithersburg, MD and company can be reached via phone at +240 6313200.
Emergent BioSolutions company profile:
Emergent BioSolutions Inc.
emergentbiosolutions.comExchange:
NYSE
Full time employees:
1,600
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
400 Professional Drive
Gaithersburg, MD 20879
Gaithersburg, MD 20879
CIK: 0001367644
ISIN: US29089Q1058
CUSIP: 29089Q105
